PFA
CLBT icon

Pathway Financial Advisers’s Cellebrite CLBT Stock Holding History

Pathway Financial Advisers’s Portfolio CLBT Stock Details CLBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-260
Closed -$5.73K – 199
2024
Q4 		$5.73K Sell
260
-4,118
-94% -$79.3K ﹤0.01% 393
2024
Q3 		$260 Buy
4,378
+4,118
+1,584% +$61.1K ﹤0.01% 396
2024
Q2 		$3.11K Hold
260
– – ﹤0.01% 415
2024
Q1 		$2.88K Hold
260
– – ﹤0.01% 422
2023
Q4 		$2.25K Hold
260
– – ﹤0.01% 443
2023
Q3 		$1.99K Buy
+260
New +$1.95K ﹤0.01% 453

Other funds holding CLBT

TWCM
True Wind Capital Management San Francisco, California $226M AUM 2.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AE
Axon Enterprise Scottsdale, Arizona $19.1M AUM 8.75% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Pathway Financial Advisers's CLBT Position: Q1 2025 in Review

Pathway Financial Advisers sold out of Cellebrite (CLBT) in Q1 2025, closing a stake of 260 shares — an estimated $5.73K sold.

Pathway Financial Advisers first reported a position in CLBT in Q3 2023 and held it in 6 quarters. The position peaked at $5.73K in Q4 2024. 199 funds tracked by Wall St. Rank hold CLBT as of Q1 2025.

  • Pathway Financial Advisers reported no remaining Cellebrite position as of Q1 2025 after selling out during the quarter.
  • Pathway Financial Advisers sold 260 Cellebrite shares in Q1 2025, an estimated $5.73K.
  • Pathway Financial Advisers first reported a position in Cellebrite in Q3 2023 and held it in 6 quarters.
  • Pathway Financial Advisers's Cellebrite position peaked at $5.73K in Q4 2024.
  • 199 funds tracked by Wall St. Rank held Cellebrite as of Q1 2025.

Based on Pathway Financial Advisers's 13F filing for Q1 2025, filed 9 May 2025.